Novel anti-hepatitis B agents: A focus on telbivudine

International Journal of Clinical Practice

Volumn 60, Issue 10, 2006, Pages 1295-1299

  Jones, Rachael ^a   Nelson, M ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Hepatitis B; Novel agents; Telbivudine

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; ANTIVIRUS AGENT; CLEVUDINE; CORE PROTEIN; CREATINE KINASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; PEGINTERFERON ALPHA2A; PRADEFOVIR; PROTEIN PRECURSOR; TELBIVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VALTORCITABINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; CHRONIC LIVER DISEASE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; FATIGUE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TOXICITY; MUTATIONAL ANALYSIS; NEPHROTOXICITY; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; VACCINATION;

ANTIVIRAL AGENTS; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE II AS TOPIC; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HUMANS; NUCLEOSIDES; PYRIMIDINONES; VIRAL CORE PROTEINS;

EID: 33748541588     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01143.x     Document Type: Review

References (18)

1. Available at: http://www.cdc.gov/.
2. Available at: http://www.who.int/.
3. Available at: http://www.cdc.gov/nchs/nhanes.htm.
4. Iloeje U, Yang H, Su J et.al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-86.
5. Chen C, Yang H, Su J et.al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
6. Seifer M, Patty A, Dukhan D et.al. Telbivudine (LdT) preferentially inhibits second (+) strand HBV DNA synthesis [Abstract]. Digestive Disease Week 2005, Chicago, IL. Gastroenterology 2005; 128: A742-3.
7. Bridges E. Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity, or carcinogenicity [Abstract]. 41st Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria. J Hepatol 2006; 44 (Suppl. 2): S147.
8. Lai C, Leung N, Teo E et.al. Phase IIb extended treatment trial of telbivudine (LdT) vs. lamivudine (3TC) vs. combination treatment in hepatitis B patients: Two-year results [Abstract]. Digestive Disease Week 2005, Chicago, IL. Gastroenterology 2005; 128: A692.
9. Lai CL, Leung N, Teo EK et.al. A one-year trial of telbivudine, lamivudine, and the combination in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2005; 129: 528-36.
10. Bzowej N, Lai C, Gane L et.al. Phase III comparison of telbivudine vs lamivudine in patients with chronic hepatitis B: Efficacy, safety, and predictors of response at 1 year [Abstract]. Gastroenterology 2006; 130 (Suppl. 2): A765-6.
11. Hou J, Yin Y, Xu D et.al. A phase III comparative trial of telbivudine and lamivudine for treatment of chronic hepatitis B in Chinese patients: first year results [Abstract]. J Gastroenterol Hepatol 2006; 21 (Suppl. 2): A128-9.
12. Heathcote E, Chan H, Cho M et.al. A randomized trial of telbivudine (LdT) vs. adefovir for HBeAg-positive chronic hepatitis B: Results of the primary week 24 analysis [Abstract]. Gastroenterology 2006; 130 (Suppl. 2): A765.
13. Hadziyannis S, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-24.
14. Wai C, Fontana R. Clinical significance of hepatitis B virus genotypes, variants, and mutants. Clin Liver Dis 2004; 8: 321-52.
15. Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999; 29: 976-84.
16. Rodriguez-Frias F, Buti M, Jardi R et.al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology 1995; 22: 1641-7.
17. Naoumov N, Lai CL, Gane E et.al. Effect of core promoter/precore mutation pattern and early virologic response on efficacy outcomes with telbivudine in HBeAg-negative chronic hepatitis B [Abstract]. J Hepatol 2006; 44 (Suppl. 2): S276.
18. Standring DN, Seifer M, Patty A et.al. HBV resistance determination from the telbivudine GLOBE registration trial [Abstract]. J Hepatol 2006; 44 (Suppl. 2): S191.